Browse the evidence

Adipose tissue directly secretes pro-inflammatory cytokines (TNF-alpha, IL-6) and acute-phase proteins (PAI-1, haptoglobin) in obesity, contributing to elevated circulating levels and metabolic comorbidities.

Fat tissue is not just inert storage; it actively releases inflammatory proteins that harm metabolic health. Reducing fat mass can reduce this source of inflammation.

Adiponectin is an anti-inflammatory adipokine whose levels decrease in obesity, contrasting with most other adipokines that increase.

Maintaining healthy adiponectin levels, often associated with lower body fat and exercise, may help reduce inflammation and improve insulin sensitivity.

Insulin resistance is a primary antecedent metabolic abnormality in many patients with NAFLD and NASH, driving fat accumulation and potentially hepatocellular injury.

Managing insulin resistance through lifestyle changes is a key strategy for addressing the root cause of fatty liver disease. This involves weight management, exercise, and dietary adjustments to improve how the body handles insulin.

Adiponectin, an adipocyte-secreted protein, has cardioprotective effects, and its levels are decreased in obesity, contributing to increased cardiovascular risk.

Low levels of adiponectin, a hormone produced by fat cells, are linked to higher heart disease risk. Since adiponectin levels drop in obesity, losing weight and improving metabolic health are the most effective ways to restore these protective levels and support heart health.

Obesity-induced inflammation involves a shift in adipose tissue macrophages from an anti-inflammatory M2 state to a pro-inflammatory M1 state, which secretes cytokines like TNF-α that block insulin signaling.

In obese individuals, fat tissue isn't just storage; it becomes an active immune organ. Fat cells attract immune cells that switch to a 'pro-inflammatory' mode (M1 macrophages), releasing chemicals like TNF-α that block insulin from working properly. Reducing this specific type of immune activation in fat tissue is key to improving metabolic health.

Inhibition of specific inflammatory signaling pathways (NF-κB and JNK) can disrupt the link between obesity and insulin resistance, suggesting these pathways are therapeutic targets.

Targeting the specific inflammatory signaling pathways (like JNK and NF-κB) that are overactive in obesity may help restore insulin sensitivity. While drugs targeting these are in development, current lifestyle interventions that reduce overall inflammation may indirectly modulate these pathways.

Women with type 2 diabetes face a disproportionately higher risk of cardiovascular disease, myocardial infarction, and stroke mortality compared to men, as diabetes attenuates the natural cardioprotective effects of the female sex.

Women with type 2 diabetes should be monitored for cardiovascular health more aggressively than men, as the disease removes their natural hormonal protection against heart disease and stroke. This includes regular screening for cardiac risks even if traditional male-centric risk factors appear controlled.

Pathological adipose tissue expansion driven by adipocyte hypertrophy leads to local hypoxia, which triggers a fibrotic response and chronic inflammation, ultimately resulting in systemic insulin resistance.

Not all fat gain leads to metabolic disease. The key is how your body handles the expansion. If your fat cells grow too large (hypertrophy) without creating new blood vessels, they become hypoxic and inflamed, causing insulin resistance. Encouraging 'healthy' expansion (hyperplasia/new cell creation) through gradual weight management may help preserve metabolic health, whereas rapid, massive fat cell enlargement is the primary driver of pathology.

Macrophage infiltration into adipose tissue is a critical mediator of obesity-induced insulin resistance, and their removal can restore insulin sensitivity.

Chronic inflammation in fat tissue, driven by immune cells called macrophages, is a major cause of insulin resistance. Reducing this inflammation, potentially by shifting macrophages from a pro-inflammatory (M1) to an anti-inflammatory (M2) state, could improve metabolic health.

Obesity-induced adipose tissue dysfunction, characterized by hypertrophy and macrophage infiltration, drives systemic insulin resistance and metabolic disease through the dysregulated secretion of pro-inflammatory adipokines (e.g., TNF-α, IL-6, MCP-1) and elevated free fatty acids, rather than fat mass alone.

Focus on improving metabolic health through actions that reduce adipose tissue inflammation, not just weight loss. Strategies that improve adipose tissue function (like exercise which can alter macrophage polarization) may be more effective for insulin sensitivity than caloric restriction alone, especially if you have 'dysfunctional' obesity.

High baseline insulin and/or glucose levels predict favorable treatment effects from bariatric surgery, whereas high baseline BMI does not.

Patients with high insulin or glucose levels, even if their BMI is not extremely high, may benefit significantly from bariatric surgery. This suggests that current BMI-based selection criteria might be too restrictive and that metabolic health should be a key factor in deciding who gets surgery.

Adult humans possess active brown adipose tissue (BAT) capable of thermogenesis, primarily located in supraclavicular and neck regions, which is acutely activated by cold exposure via sympathetic nervous system stimulation.

Adults likely have functional brown fat in their neck and collarbone area. It activates when you are cold, burning energy and helping clear glucose from your blood. You don't need to do anything special to have it, but you need to be cold enough for it to turn on. This challenges the old idea that adults don't have this fat.

Activation of the nuclear receptor FXR by bile acids or synthetic agonists lowers plasma triglycerides and improves hyperglycemia in diabetic models.

While you cannot directly 'dose' bile acids safely without medical supervision, the paper suggests that modulating bile acid metabolism (e.g., via FXR agonists) is a promising pharmacological strategy for treating metabolic syndrome and type 2 diabetes. For now, maintaining a healthy gut microbiome supports normal bile acid cycling, which is linked to metabolic health.

Bile acids regulate energy expenditure through a pathway independent of FXR, mediated by the G-protein coupled receptor TGR5.

TGR5 activation by bile acids contributes to energy expenditure. This highlights the importance of gut health and bile acid composition for metabolic rate, independent of just fat digestion.

In patients with nonalcoholic steatohepatitis (NASH), older age, obesity, and diabetes mellitus are independent predictors of severe liver fibrosis (bridging fibrosis or cirrhosis).

If you have NASH, your risk of severe liver scarring is highest if you are older, obese, or have diabetes. Focus on managing blood sugar and achieving a healthy weight, as these factors drive the scarring process more than the amount of fat in the liver itself. Regular monitoring via biopsy or advanced testing is recommended for this high-risk group.

The risk reduction from salt reduction is independent of baseline blood pressure, suggesting mechanisms beyond just blood pressure lowering.

Even if your blood pressure is normal, high salt intake can damage your heart muscle and arteries directly. Reducing salt protects your heart structure, not just your numbers.

Sleep deprivation reduces the responsiveness of the circadian clock (SCN) to light, potentially mediated by adenosine blocking glutamate release.

Consistent sleep is required for your body to effectively respond to light cues for resetting your circadian rhythm. Sleep deprivation blunts this response.

Activation of the gut microbiota-derived short-chain fatty acid receptor GPR43 in adipose tissue suppresses insulin signaling, thereby inhibiting fat accumulation and promoting energy expenditure.

To leverage this mechanism, prioritize dietary fiber intake to support gut bacteria that produce short-chain fatty acids (like acetate). These SCFAs activate GPR43 receptors in fat tissue, which helps suppress insulin-driven fat storage and promotes energy expenditure. This suggests that a high-fiber diet may support weight management through hormonal signaling, not just calorie reduction.

Hyperinsulinemia and insulin resistance are common pathophysiological features linking hypertension, obesity, and glucose intolerance, potentially explaining their ubiquitous association through mechanisms involving elevated intracellular sodium and increased peripheral vascular resistance.

If you have high blood pressure, especially if you are not obese, check your metabolic health. High insulin levels (hyperinsulinemia) and insulin resistance are strongly linked to hypertension, independent of obesity. Managing insulin sensitivity through diet and lifestyle may be as important for blood pressure control as reducing sodium intake.

Satellite cell fusion and the addition of new myonuclei are essential for muscle growth during early postnatal development but are not required for hypertrophy in adult skeletal muscle induced by most stimuli (e.g., reloading, androgens).

In adults, you can build muscle through increased protein synthesis without necessarily adding new nuclei (satellite cell fusion), especially with gradual training. Satellite cell fusion is more critical during development or after significant muscle damage.

Metformin is the first-line oral pharmacological treatment for Type 2 Diabetes Mellitus (T2DM) across all age groups, primarily by activating AMPK to inhibit hepatic gluconeogenesis and sensitizing peripheral tissues to insulin.

Metformin is the standard first-line medication for Type 2 Diabetes. It works by helping your liver produce less sugar and your body use insulin better. It typically lowers blood sugar by 1-2% without causing weight gain. If you have kidney issues, your doctor may adjust the dose or avoid it. Start with a low dose to minimize stomach upset.

In obese humans, circulating leptin levels are elevated while ghrelin levels are decreased, and the body exhibits leptin resistance, meaning high leptin fails to suppress food intake or increase energy expenditure as it does in lean individuals.

If you are obese, your body likely has high levels of leptin (the 'stop eating' hormone) and low levels of ghrelin (the 'start eating' hormone), but your brain has become resistant to these signals. This is why standard dieting often fails; your body fights back by ignoring the satiety signals. Understanding this resistance explains why simply 'trying harder' is physiologically difficult and why treatments must address the signaling pathway, not just hormone levels.

Leptin resistance in obesity is likely caused by defective transport of leptin across the blood-brain barrier (BBB) and/or downregulation of hypothalamic leptin receptors, rather than a lack of leptin production.

Standard leptin injections do not work for most obese people because the hormone cannot cross the blood-brain barrier efficiently or the brain receptors are downregulated. This is why 'leptin diets' or supplements are ineffective for common obesity. Effective interventions must either bypass the blood-brain barrier or target downstream pathways.

Ghrelin functions as a meal-initiation signal in humans, with preprandial increases correlating with hunger, and its levels are suppressed by food intake, although its role in long-term weight regulation is less clear than leptin's.

Ghrelin is your body's 'start eating' signal. It rises before meals and drops after. In obesity, ghrelin levels are actually lower than in lean people, but the system may be oversensitive. Understanding that hunger is a hormonal signal helps normalize the experience of hunger as a biological event, not a failure of will.